1. Home
  2. CYTK vs FORM Comparison

CYTK vs FORM Comparison

Compare CYTK & FORM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$72.72

Market Cap

10.7B

Sector

Health Care

ML Signal

N/A

Logo FormFactor Inc. FormFactor Inc.

FORM

FormFactor Inc. FormFactor Inc.

N/A

Current Price

$103.90

Market Cap

9.0B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
CYTK
FORM
Founded
1997
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
10.7B
9.0B
IPO Year
2004
2002

Fundamental Metrics

Financial Performance
Metric
CYTK
FORM
Price
$72.72
$103.90
Analyst Decision
Strong Buy
Buy
Analyst Count
19
9
Target Price
$89.26
$98.25
AVG Volume (30 Days)
1.8M
980.6K
Earning Date
05-05-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.96
Revenue
$13,368,000.00
N/A
Revenue This Year
$7.37
$19.43
Revenue Next Year
$310.19
$7.31
P/E Ratio
N/A
$100.67
Revenue Growth
N/A
N/A
52 Week Low
$47.22
$29.01
52 Week High
$88.31
$160.27

Technical Indicators

Market Signals
Indicator
CYTK
FORM
Relative Strength Index (RSI) 42.80 37.87
Support Level $73.34 $92.85
Resistance Level $79.73 $105.71
Average True Range (ATR) 2.22 6.42
MACD -0.38 -2.32
Stochastic Oscillator 39.09 9.61

Price Performance

Historical Comparison
CYTK
FORM

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About FORM FormFactor Inc. FormFactor Inc.

FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.

Share on Social Networks: